wr 194965

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WR 194965: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	129635
CHEMBL ID	174301
SCHEMBL ID	15674488
MeSH ID	M0130296

Synonyms (16)

Synonym
NCI60_002600 ,
69121-82-0
CHEMBL174301
4-tert-butyl-2-[(tert-butylamino)methyl]-6-(4-chlorophenyl)phenol
(1,1'-biphenyl)-2-ol, 4'-chloro-5-(1,1-dimethylethyl)-3-(((1,1-dimethylethyl)amino)methyl)-
wr 194,965
wr 194965
wr-194,965
DTXSID90219184
SCHEMBL15674488
wr-194965
PD160560
4RD6V6BLX8
4'-chloro-5-(1,1-dimethylethyl)-3-[[(1,1-dimethylethyl)amino]methyl][1,1'-biphenyl]-2-ol
[1,1'-biphenyl]-2-ol, 4'-chloro-5-(1,1-dimethylethyl)-3-[[(1,1-dimethylethyl)amino]methyl]-
butyl)-2-(tert-butylaminomethyl)-6-(4-chlorophenyl)phenol, 4-(tert-

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID135291	Antimalarial activity as 60-day survivors in Plasmodium berghei infected mice (Mus musculus) after single 160mg/kg subcutaneous dose 72 hr post infection	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129942	Difference in mean survival time in mice (Mus musculus) (control = 6.2 days) after single 40mg/kg subcutaneous dose 72hr post infection	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129945	Change in mean survival time for control (average of 6.2 days) versus treated mice (Mus musculus) 72 hrs after 80 mg/kg subcutaneous dose	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID135296	Antimalarial activity, administered as a single subcutaneous dose of 640 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID135293	Antimalarial activity as 60-day survivors in infected mice (Mus musculus) after single 320mg/kg subcutaneous dose 72 hr post infection	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129940	Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 20 mg/kg subcutaneous dose	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (85.71)	18.7374
1990's	1 (14.29)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.21 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.29 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.38	2	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.66	3	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
pyrimethamine Maloprim: contains above 2 cpds	2.38	2	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
halofantrine halofantrine: used in treatment of mild to moderate acute malaria	2.66	3	phenanthrenes
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	1.97	1	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
tebuquine [no description available]	2.65	3
wr 99210 BRL 6231: RN given refers to parent cpd; NM & N1 refer to HCl; synonym BRL 51084 refers to (mono-HBr); structure	1.97	1
wr 184806 WR 184806: internal std for chromatographic anal of mefluquine; RN given refers to (+-)-isomer; structure given in first source	1.97	1
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	1.97	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
wr 225448 WR 225448: used as prophylaxis for Plasmodium yoelii infections; structure given in first source	2.37	2
sesquiterpenes [no description available]	1.97	1
enpiroline enpiroline: structure	2.66	3
quinine [no description available]	2.38	2	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
alpha-(2-piperidyl)-3,6-bis(trifluoromethyl)-9-phenanthrenemethanol alpha-(2-piperidyl)-3,6-bis(trifluoromethyl)-9-phenanthrenemethanol: structure	1.97	1
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	2.89	4
amodiaquine hydrochloride [no description available]	1.96	1
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.66	3

Condition	Indicated	Relationship Strength	Studies	Trials
Infections, Plasmodium [description not available]	0	2.37	2	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	0	7.37	2	0

chemdatabank.com